Business

VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT DRUG LIST ADJUSTMENT

VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT DRUG LIST ADJUSTMENT

articlePegbio Co., Ltd. Class HJune 29, 20265/news/voluntary-announcement-core-product-visepegenatide-injection-passed-the-preliminary-review-in-accordance-with-the-2026-national-reimbursement-drug-list-adjustment
VOLUNTARY ANNOUNCEMENT CORE PRODUCT VISEPEGENATIDE INJECTION PASSED THE PRELIMINARY REVIEW IN ACCORDANCE WITH THE 2026 NATIONAL REIMBURSEMENT DRUG LIST ADJUSTMENT

About this update from Pegbio Co., Ltd. Class H

Pegbio Co., Ltd. Class H (2565) Press ReleaseView Attachment

View stock analysis, news, and events for Pegbio Co., Ltd. Class H